Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

NCT07197554 is registered in ClinicalTrials.gov with SEED Therapeutics, Inc. as lead sponsor.

NCT NCT07197554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07197554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Lead sponsor
SEED Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 1, 2025
Completion date
December 31, 2029
Enrollment
171 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, biliary tract cancer (btc), ewing sarcoma, hepatocellular carcinoma (hcc)